EntryPoint Capital LLC Purchases 47,113 Shares of Accolade, Inc. (NASDAQ:ACCD)

EntryPoint Capital LLC grew its position in shares of Accolade, Inc. (NASDAQ:ACCD) by 128.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 83,787 shares of the company’s stock after buying an additional 47,113 shares during the quarter. EntryPoint Capital LLC’s holdings in Accolade were worth $287,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ACCD. Pallas Capital Advisors LLC acquired a new position in shares of Accolade in the 4th quarter worth approximately $38,000. Mission Creek Capital Partners Inc. bought a new position in Accolade in the 3rd quarter valued at $38,000. Wolverine Trading LLC acquired a new position in Accolade in the third quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of Accolade by 1,144.1% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company’s stock worth $81,000 after purchasing an additional 19,232 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Accolade in the third quarter valued at $96,000. Institutional investors and hedge funds own 84.99% of the company’s stock.

Accolade Stock Up 0.1 %

NASDAQ:ACCD opened at $7.00 on Friday. Accolade, Inc. has a 1 year low of $3.08 and a 1 year high of $10.68. The stock has a 50-day moving average price of $6.93 and a two-hundred day moving average price of $4.93. The stock has a market cap of $573.95 million, a price-to-earnings ratio of -3.11 and a beta of 2.18. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67.

Accolade (NASDAQ:ACCD) last issued its quarterly earnings data on Friday, January 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.01. Accolade had a negative return on equity of 20.74% and a negative net margin of 40.36%. As a group, equities analysts expect that Accolade, Inc. will post -1.2 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Leerink Partnrs downgraded shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Leerink Partners reissued a “market perform” rating on shares of Accolade in a research note on Wednesday, January 8th. Morgan Stanley dropped their price objective on shares of Accolade from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Truist Financial lowered Accolade from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th. Finally, Piper Sandler downgraded Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Thirteen analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, Accolade has an average rating of “Hold” and an average price target of $6.51.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.